Artur Schmidtchen

Corporate Officer/Principal at University of Lund

Health Technology

Consumer Services

Profile

Artur Schmidtchen is the founder of Sista versen 26366 AB, founded in 2009, and DermaGen AB, founded in 2004.
At DermaGen AB, he held the title of Director from 2004 to 2011.
Currently, Dr. Schmidtchen is a Professor at the University of Lund.

Artur Schmidtchen active positions

Companies	Position	Start
University of Lund	Corporate Officer/Principal	-

All active positions of Artur Schmidtchen

Former positions of Artur Schmidtchen

Companies	Position	End
Sista versen 26366 AB Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden.	Founder	-
DermaGen AB DermaGen AB Pharmaceuticals: MajorHealth Technology DermaGen AB develops drugs and medical devices. It focuses on the development of topically applied products for the prevention and treatment of bacterial and fungal skin infections. The company was founded on February 2, 2004 and is headquartered in Solna, Sweden.	Founder	-

See the detail of Artur Schmidtchen's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Artur Schmidtchen's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
DermaGen AB DermaGen AB Pharmaceuticals: MajorHealth Technology DermaGen AB develops drugs and medical devices. It focuses on the development of topically applied products for the prevention and treatment of bacterial and fungal skin infections. The company was founded on February 2, 2004 and is headquartered in Solna, Sweden.	Health Technology
Sista versen 26366 AB Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden.	Health Technology